Privacy Policy

This site is operated by Virtus Pharmaceuticals, LLC (“Virtus”) and Acertis Pharmaceuticals, LLC (“Acertis”). Our Privacy Policy is designed to tell you about the policies that govern our collection, use, and disclosure of the information that you may provide via our Websites. Before using or submitting information to this site, please read this entire Private Policy. Please be aware that this Privacy Policy generally describes Virtus and Acertis sites, although the particular site you are viewing may not include all the items described. This site is governed solely by applicable Federal and State laws and governmental regulations in the United States. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy.

Information Use and Disclosure

Your name, address, e-mail address, and any other personally identifiable information you provide may be used by Virtus and Acertis, its business partners and consultants to provide you with information about Virtus and Acertis products, or health issues, or to develop services concerning health conditions. Virtus and Acertis will not sell or rent the personally identifiable information collected via this site to a third party. We reserve the right to disclose information to respond to duly authorized information requests of governmental authorities or where required by law.

You can notify Virtus and Acertis that you wish to discontinue receiving information at any time (see How To Contact Us below).

By using this site, you agree with the terms of this Privacy Policy. Whenever you submit information via this site, you consent to the collection, use, and disclosure of that information in accordance with this Privacy Policy.

We may use your information to improve the value of our site’s content, to present the site in a fashion customized to match your preferences, to supply information to you (if you requested it), for research and marketing purposes, and for the purposes specified in this Privacy Policy.

We may combine personally identifiable information with other actively collected information unless we specify otherwise at the point of collection. Virtus and Acertis will take reasonable measure to prevent passively collected information from being combined with personally identifiable information, unless you consent otherwise.

We will also make full use of all information acquired through this site that is not personally identifiable.

Access and Updates

To keep your personally identifiable information accurate, current, and complete, please contact us as specified below. We will take reasonable steps to update or correct personally identifiable information in our possession that you have previously submitted via this site.


Please bear in mind that no Internet transmission is ever 100% secure or error-free. More specifically, e-mail sent to or from this site may not be secure. As a result, you should take particular care in deciding what information you send via e-mail. Any passwords, ID numbers, or other special access numbers you might use to access any part of this site are your responsibility; take care to safeguard them. Virtus and Acertis take reasonable steps to protect your personally identifiable information from loss, misuse, and unauthorized access, disclosure, alteration, or destruction, but cannot insure that these effects will not happen.

Links to Other Websites

Links or references to other Websites may appear within this site. We do not control these Websites. You should be aware that this Privacy Policy does not apply to any Websites other than those operated by Virtus and Acertis. Visitors to other Websites are encouraged to read their privacy policies before exploring them.

About Children

Children under the age of 13 are not the intended audience for this site. We will not knowingly collect information from site visitors in this age group. We encourage parents to be aware of their children’s use of the Internet and discuss what kind of information they are allowed to disclose to Websites.

Active Information Collection

This site may actively collect information from its visitors both by asking them specific questions and by facilitating direct communications with us via e-mail, feedback forms, etc. Some of the information that visitors submit may be personally identifiable information (this is, information that can be uniquely identified with an individual, such as full name, address, e-mail address, phone number, and so on).

In some cases we might collect non-personally identifiable information that you elect to provide voluntarily, such as gender or zip code.

This site may also offer some features and activities (such as newsletter subscriptions, downloads, etc.) which may require you to submit information in order to receive or benefit from them. You will be informed at each information collection point what information is required and what information is optional.

Passive Information Collection

Like many other websites, this site may also collect some information passively as you navigate through the site (that is, this information is gathered without your actively providing the information), using various technologies and means, such as navigational data collection.

Navigational data (“log files,” “server logs,” and “clickstream” data) are used for system management, to improve the content of the site, market research purposes, and to communicate information to visitors. This site may or may not use navigational data.

One of the ways information may be passively collected is by the use of Internet Protocol (IP) addresses. An IP address is a number assigned to your computer by your Internet service provider so you can access the Internet. IP addresses are generally considered to be non-personally identifiable information, because most IP addresses are dynamic (they change each time you connect to the Internet), rather than static (unique to any one particular user’s computer). We may use your IP address to improve or administer the site, diagnose server problems, report aggregate information, or to determine the fastest connection route between your computer and our site.

Another method for passive information collection is by means of “cookies.” A “cookie” is a small data text file, which a Website stores on your computer’s hard drive (if your Web browser permits) that can later be retrieved to identify you. “Session cookies” are temporary bits of information that are erased once you exit your Web browser window or otherwise turn your computer off. Session cookies are used to improve navigation on Websites and to collect aggregate statistical information.

This site may use both cookies and session cookies. If you do not wish to receive cookies from this or any other site, you can change your computer’s settings so that it will no longer accept cookies.

Turning off cookies

Cookies are small files that a site or its service provider transfers to your computer's hard drive through your web browser (if you allow) that enables the site's or service provider's systems to recognize your browser and capture and remember certain information. We may use cookies to help us compile aggregate data about Site traffic and Site interaction.

How to Contact Us

If you have any questions, comments, or concerns about this Privacy Policy or the information collection practices of this site, please contact us at:

Virtus Pharmaceuticals, LLC
Attn: General Counsel
2050 Cabot Blvd. West
Suite 200
Langhorne, PA 19047

Acertis Pharmaceuticals, LLC
Attn: General Counsel
2050 Cabot Blvd. West
Suite 200A
Langhorne, PA 19047

Changes to This Privacy Policy

Virtus and Acertis reserve the right to modify, add or remove portions of this privacy policy at its discretion. Any changes to this Privacy Policy will be posted on this site. Please check back periodically, and especially before you provide any personally identifiable information. This Privacy Policy was last updated on July 3 2019.

Other Terms: Your use of this site is subject to our  Legal Notice.

Anthony W. Amato

Chief Executive Officer

After practicing law for several years, Tony started his career in pharmaceuticals in business development at Barr Labs. During his tenure at the company, Barr acquired proprietary women’s health products, Plan B and Paragard, and in-licensed transdermals, ophthalmics and nasal sprays, rapidly expanding beyond its generic solid oral dose portfolio. Barr was eventually acquired by Teva for $7.5B in 2008. Tony next headed up US business development at Lupin Pharmaceuticals and led the aggressive expansion into high margin brand products, diversifying Lupin’s product portfolio. In 2014 Tony joined Alvogen and rose to the position of Sr. Vice President Business Development and Alliance Management, completing multiple transactions and deploying over $500M capital in five years to expand the generic portfolio into injectables and inhalation drug forms and grow its branded business, Almatica, through the acquisition of highly profitable mature products and patent protected Psychiatry/CNS approved and pipeline products as well as biosimilars.

Tony was named CEO of Virtus in 2022 and is re-positioning the company by building verticals focused on retail and institutional generics, brands, consumer health and biosimilars, employing innovative business models and deal structures that will benefit its partners and, ultimately, patients.

Debra Cesard

Chief Financial Officer

Debra re-joined Virtus as Chief Financial Officer in March 2022, previously serving in that role through 2020. She is an accomplished financial manager with 25+ years of experience having previously worked for a “Big 4” accounting firm and emerging and established global brand and generic pharmaceutical companies including AdvaGen, Sandoz and Bristol-Myers Squibb. She possesses outstanding problem-solving abilities and impeccable integrity. A strategic-minded yet hands-on leader recognized for establishing cross functional collaboration as a business partner, initiating and managing change, developing high performing teams, as well as planning and executing corporate strategies and company- wide initiatives.

Debra is a Certified Public Accountant (inactive) and holds a Bachelor of Science in Accounting from Rutgers University.

Michael Proctor

Head of Promoted Products

Michael “Mickey” Proctor joined Virtus Pharmaceuticals, LLC in January 2022 as Head of Promoted Products. Mickey is an experienced veteran of the pharmaceutical industry with 43+ years of experience with brands and generics and start-up to global leading companies. He has served in executive leadership positions for 20+ years building strong performance teams among sales, marketing, managed care and account management. He created the commercial organization and launched the Suprax® brand to exceed $100M in a generic market with no patent protection.

Mickey holds a Bachelors of Arts and Bachelors of Science in Marketing, Ohio State University.

Myrl Vossler

Head of Generics

Myrl joined the company in February 2022, and serves as Head of Generics, Virtus Pharmaceuticals. He has 15 years of experience leading sales, marketing, and supply chain operations with new and established ventures across the pharmaceutical industry. Myrl has developed and executed numerous programs to successfully penetrate markets, retain accounts and control inventory while strengthening business relationships and profitability across key customers.

Myrl holds a Bachelor of Science degree from the University of Central Missouri.

Matthew Prokopczyk

Senior Vice President, Quality and Regulatory

Matthew serves as Senior Vice President, Quality and Regulatory, Virtus Pharmaceuticals bringing 25+ years of experience with brand and generic pharmaceutical companies. Prior to joining Virtus in February 2022, he held leadership positions of Quality and Regulatory functions at Aphena, Amerigen, Alvogen, Dr. Reddy’s and Wyeth. He is an accomplished veteran of the industry with a proven track record of building and leading compliant, efficient, quality organizations.

Matthew holds an MBA in Finance and Business Economics from Fordham University, NY and a Bachelor of Science Degree from the College of Mount Saint Vincent, NY.

Ashleigh Preiss

Vice President, Operations and Alliance Management

Ashleigh joined Virtus in August 2013 and serves as the Vice President, Operations and Alliance Management. She has extensive experience with the Virtus supply chain and logistics processes and partnerships to maintain inventory and support excellent customer service. Prior to her current role Ashleigh held positions of increasing responsibility as: Director, Supply Chain, Associate Director, Procurement and Logistics and Customer Service Analyst.

Ashleigh holds a Bachelors of Arts in Communication Sciences and Disorders, University of South Florida and a Bachelors of Science, Sport Management, California University, PA and is currently studying for a Master of Science in Public Health, Applied Studies, University of Florida Graduate School of Public Health and Certification in Production and Inventory Management (APICS).

Sandra Shook

Director of Human Resources

Sandra joined Virtus in April 2017 and serves as the Director of Human Resources. She has 25+ years of experience in human resource functions, issues, employment law and organizational development. She has served in positions of increasing responsibility with a specialty and global generic pharmaceutical leader. She is responsible for all human resource functions and objectives that provide an employee-oriented; high performance culture that emphasizes empowerment, quality productivity, standards and the recruitment and ongoing development of a superior workforce.

Sandra holds a Bachelor of Science in Business Administration, Albright College, PA

David Friedman

Head, Strategy and Business Development

David has over 30 years experience providing a wide range of corporate advisory services to clients in healthcare and related industries. Clients have included life sciences companies Novartis, Boehringer Ingelheim, Endo, Par Pharmaceutical, Lannett, Lupin, JHP Pharmaceuticals, G&W Laboratories and Ranbaxy. David holds a BA (History - Honors) from Haverford College and an MBA (Finance) from The Wharton School, University of Pennsylvania. He also studied at the London School of Economics.